Mergers & Acquisitions - Biotechnology


Current filters:


Popular Filters

76 to 100 of 261 results

Merck KGaA eighth EPP spin-off to focus on infertility treatment

Merck KGaA eighth EPP spin-off to focus on infertility treatment


USA-based EMD Serono, one of German drug and chemical group Merck KGaA’s biotechnology subsidiaries,…

BiotechnologyEMD SeronoMerck KGaAMerck SeronoMergers & AcquisitionsReproductiveResearchTocopheRx

Korea’s SillaJen to acquire Jennerex in up to $150 million deal

Korea’s SillaJen to acquire Jennerex in up to $150 million deal


Privately-held South Korean firm SillaJen says it has executed a definitive merger agreement to acquire…

BiotechnologyJennerexMergers & AcquisitionsOncologyPexa-VecSillaJenTransgene

Clovis Oncology buys Italian firm for $200 million


US biotech firm Clovis Oncology says it has acquired EOS (Ethical Oncology Science), a privately-held…

BiotechnologyClovis OncologylucitanibMergers & AcquisitionsOncologyServier

Aphios spins off Amylon to develop novel Alzheimer’s disease drug


US clinical-stage biotech firm Aphios says it has spun-off a subsidiary, Amylon, to finance, develop…

AmylonAPH-1104AphiosBiotechnologyFinancialMergers & AcquisitionsNeurologicalResearch

Collaboration agreement between French firms Vect-Horus and AAA


French biotech company Vect-Horus has signed a scientific collaboration agreement with Advanced Accelerator…

Advanced Accelerator ApplicationsBiotechnologyCNS DiseasesEuropeLicensingMergers & AcquisitionsVect-Horus

Sorrento to acquire Concortis Biosystems, gaining ADC technology

Sorrento to acquire Concortis Biosystems, gaining ADC technology


In a second acquisition within a month, USA-based Sorrento Therapeutics says it has entered a definitive…

BiotechnologyConcortis BiosystemsMergers & AcquisitionsSorrento Therapeutics

Rainbow Coral narrows list of regenerative medicine targets


USA-based Rainbow Coral Corp says it has opened talks with its top target in the regenerative medicine…

BiotechnologyLicensingMergers & AcquisitionsRainbow Biosciences

Report: M&A worth $11 billion in third quarter while Russian market shows promise

Report: M&A worth $11 billion in third quarter while Russian market shows promise


PricewaterhouseCoopers (PwC) has released its quarterly Life Sciences Deals Insights Quarterly for the…

BiotechnologyEuropeMarkets & MarketingMergers & AcquisitionsPharmaceutical

Vivaldi Biosciences acquires clinical stage influenza vaccine assets


Privately-held US biotech firm Vivaldi Biosciences has acquired from Baxter Healthcare R&D assets, including…

Anti-viralsBaxter HealthcareBaxter InternationalBiotechnologyMergers & AcquisitionsVaccinesVivaldi Biosciences

Osiris to sell culture-expanded MSCs business including Prochymal


USA-based Osiris Therapeutics has entered into an agreement with a wholly-owned subsidiary of Mesoblast…

BiotechnologyFinancialMergers & AcquisitionsMesoblastOsiris TherapeuticsProchymal

OPKO makes strategic investment in biotech firm


US pharma and diagnostics firm OPKO Health has agreed to make an undisclosed strategic investment in…

BiotechnologyMergers & AcquisitionsOPKO HealthPharmaceuticalZebra Biologics

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease


PharmAkea Therapeutics and Bay City Capital have entered a strategic collaboration with Celgene designed…

BiotechnologyCelgeneMergers & AcquisitionsNorth AmericaOncologyPharmAkeaResearch

Cellceutix acquires PolyMedix assets from bankruptcy court


US clinical-stage biopharma firm Cellceutix (OTCBB: CTIX) has acquired substantially all of the assets…

BiotechnologybrilacidinCellceutixMergers & AcquisitionsPharmaceuticalPolyMedixPrurisol

Otsuka confirms takeover bid for Astex Pharmaceuticals for $886 million


Following heavy speculation on Wednesday (see The Pharma Letter story earlier today), this morning Japanese…

Astex PharmaceuticalsBiotechnologyMergers & AcquisitionsOncologyOtsukaPharmaceutical

Otsuka said to be buying Astex Pharma


Japanese mid-size drugmaker Otsuka (TYO: 4768) is planning to acquire USA-based Astex Pharmaceuticals…

Astex PharmaceuticalsBiotechnologyMergers & AcquisitionsOncologyOtsukaPharmaceutical

Sangamo BioSciences to buy Ceregene


In its first takeover bid since 2001, US drugmaker Sangamo BioSciences (Nasdaq: SGMO) has signed a definitive…

BiotechnologyCERE-110CeregeneMergers & AcquisitionsNeurologicalOphthalmicsSangamo BioSciences

Onyx Pharma accepts increased bid from Amgen


Amgen (Nasdaq: AMGN), the world largest independent biotech group, said on Sunday (August 25) that the…

AmgenBayerBiotechnologyKyprolisMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizer

AstraZeneca nabs Amplimmune for $500 million


In a further bid to expand its ailing research portfolio, Anglo-Swedish drug major AstraZeneca (LSE:…

AmplimmuneAstraZenecaBiotechnologyMergers & AcquisitionsOncologyPharmaceutical

Actelion bid for Ceptaris looks secured as FDA approves Valchlor


Privately-held USA-based Ceptaris Therapeutics revealed yesterday (August 26) that the US Food and Drug…

ActelionBiotechnologyCeptaris TherapeuticsDermatologicalsMergers & AcquisitionsNorth AmericaRegulationValchlor

Chiesi expands rare disease portfolio with acquisition


Privately-owned Italian drugmaker Chiesi Group has signed, through its UK affiliate, a definitive agreement…

BiotechnologyChiesi FarmaceuticiLamazymMergers & AcquisitionsPharmaceuticalRare diseasesZymenex

Endo unit to sell anatomical pathology business


USA-based specialty health care company Endo Health Solutions (Nasdaq: ENDP) says that its wholly owned…

BiotechnologyEndo Health SolutionshealthTronicsMergers & AcquisitionsMetamark Genetics

July a strong month for life sciences IPOs and M&A


The life sciences initial public offering (IPO) market continued to heat up in July as six life sciences…

BiotechnologyCubist PharmaceuticalsFinancialMergers & AcquisitionsPerrigoPharmaceuticalRoche

76 to 100 of 261 results

Back to top